Our latest featured trial is NCT03015623, which was registered in January 2017 but started recruiting patients in June 2017. In this trial, patients with acute kidney injury have their blood filtered through a device that holds mesenchymal stem/stromal cells from allogeneic bone marrow.
News
Duke University is the first academic center in the west to register a Phase 1 trial testing MSC infusions as therapy for autism. The MSC product will be isolated from umbilical cord tissue by enzymatic digestion, expanded in culture, and cryopreserved.
Registered in February 2017, this trial is a phase 1/2 study that compares bone marrow MSC versus umbilical cord tissue MSC for the treatment of chronic inflammation due to metabolic syndrome.
Our team checked each of the 209 entries in ClinicalTrials.gov that are supposedly open cord blood trials, and found that only 118 of these trials are conducting cell therapy with cord blood. This analysis took weeks of effort, but in the end revealed that for the exact phrase “cord blood”, only 56% of open trials found by keyword hits are active cell therapy trials.